Products for Research Use Only

Difamilast (Standard)

CAT: 0804-HY-109085R-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-109085R-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Difamilast (Standard) is the analytical standard of Difamilast. This product is intended for research and analytical applications. Difamilast (OPA-15406) is a topical, selective and nonsteroidal phosphodiesterase-4 (PDE4) inhibitor with particularly efficient inhibition of subtype B (IC50=11.2 nM) . Difamilast can be used for the research of mild to moderate atopic dermatitis (AD) [1][2][3].
CAS Number
937782-05-3
Product Name Alternative
OPA-15406 (Standard)
UNSPSC
12352005
Target
Phosphodiesterase (PDE) ; Reference Standards
Type
Reference Standards
Related Pathways
Metabolic Enzyme/Protease; Others
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/difamilast-standard.html
Smiles
CC(C)OC(C=C(C1=NC(CNC(C(C=CC=C2)=C2OCC)=O)=CO1)C=C3)=C3OC(F)F
Molecular Formula
C23H24F2N2O5
Molecular Weight
446.44
References & Citations
[1]Hanifin JM, et, al. OPA-15406, a novel, topical, nonsteroidal, selective phosphodiesterase-4 (PDE4) inhibitor, in the treatment of adult and adolescent patients with mild to moderate atopic dermatitis (AD) : A phase-II randomized, double-blind, placebo-controlled study. J Am Acad Dermatol. 2016 Aug;75 (2) :297-305.|[2]Ahluwalia J, et, al. Phosphodiesterase 4 Inhibitor Therapies for Atopic Dermatitis: Progress and Outlook. Drugs. 2017 Sep;77 (13) :1389-1397.|[3]Soeberdt M, et, al. Small molecule drugs for the treatment of pruritus in patients with atopic dermatitis. Eur J Pharmacol. 2020 Aug 15;881:173242.
Shipping Conditions
Room temperature
Scientific Category
Reference Standards

Chemical Information

Difamilast

Atopic dermatitis is a chronic and fluctuating pruritic inflammatory skin condition characterized by pruritic eczema and is also marked by exacerbations and remissions. This skin disease occurs most frequently in children and can have an onset as early as within the first 2 years of life. Difamilast is a selective PDE4 inhibitor and the inhibition of phosphodiesterase-4 (PDE4) reduces proinflammatory mediators and cytokines in atopic dermatitis. As difamilast's mechanism of action involves the inhibition of PDE4, the inhibition leads to an increase in intracellular cyclic AMP and a subsequent decrease in the production of cytokines and chemokines. The drug is indicated for the topical treatment of mild to moderate atopic dermatitis in adults and pediatric patients 2 years of age and older. It is approved in Japan and the United States.

CAS Number937782-05-3
PubChem CID57855696
IUPAC NameN-[[2-[4-(difluoromethoxy)-3-propan-2-yloxyphenyl]-1,3-oxazol-4-yl]methyl]-2-ethoxybenzamide
Molecular FormulaC23H24F2N2O5
Molecular Weight446.4
XLogP4.8
Topological Polar Surface Area82.8
Hydrogen Bond Donor Count1
Hydrogen Bond Acceptor Count8
Rotatable Bond Count10
Heavy Atom Count32
Formal Charge0
Complexity583
SMILES
CCOC1=CC=CC=C1C(=O)NCC2=COC(=N2)C3=CC(=C(C=C3)OC(F)F)OC(C)C
InChI
InChI=1S/C23H24F2N2O5/c1-4-29-18-8-6-5-7-17(18)21(28)26-12-16-13-30-22(27-16)15-9-10-19(32-23(24)25)20(11-15)31-14(2)3/h5-11,13-14,23H,4,12H2,1-3H3,(H,26,28)
InChIKey
VFBILHPIHUPBPZ-UHFFFAOYSA-N
Chemical Structure
2D Structure
2D structure of Difamilast
CAS: 937782-05-3
CID: 57855696
Formula: C23H24F2N2O5
MW: 446.4
Interactive 3D Structure
Loading 3D structure...
Computed Properties
PropertyValue
Molecular Weight446.4
XLogP34.8
Hydrogen Bond Donor Count1
Hydrogen Bond Acceptor Count8
Rotatable Bond Count10
Exact Mass446.16532819
Monoisotopic Mass446.16532819
Topological Polar Surface Area82.8 Ų
Heavy Atom Count32
Formal Charge0
Complexity583
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently-Bonded Unit Count1
Compound Is CanonicalizedYes